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ABSTRACT
It has recently been suggested that precision oncology studies should be re-analyzed using
the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
This  re-analysis  dramatically  decreases  response  rates  in  precision  medicine  studies.  We
contend that the ITT analysis of precision oncology trials is invalid. The ITT methodology was
developed three decades ago to mitigate the problems of randomized trials,  which try to
ensure that  both arms have an  unselected patient  population  free from confounders.   In
contrast,  precision  oncology  trials  specifically  select  patients  for  confounders  (that  is
biomarkers) that predict response.  To demonstrate the issues inherent in an ITT re-analysis
for precision cancer  medicine studies, we take as an example the drug larotrectinib (TRK
inhibitor) approved because of remarkable responses in malignancies harboring NTRK fusions.
According to large-scale studies,  NTRK fusions are found in ~0.31% of tumors.  In a non-
randomized pivotal study of larotrectinib, 75% of the 55 treated patients responded. Based
upon the prevalence of NTRK fusions, ~18,000 patients would need to be screened in order to
enroll  the 55 treated patients. Utilizing the ITT methodology, the revised response rate to
larotrectinib would be 0.23%. This is, of course, a dramatic underestimation of the efficacy of
this now FDA-approved drug.  Similar issues can be shown for virtually any biomarker-based
precision clinical trial.  Therefore, retrofitting the ITT analysis developed for unselected patient
populations in randomized trials yields misleading conclusions in precision medicine studies.
Perspective
Precision cancer  medicine is  defined by a strategy that requires an understanding of  the
molecular  and  biologic  characteristics  of  a  patient’s  tumor(s),  followed by  constructing  a
therapeutic  approach  that  precisely  targets  those  abnormalities.1 Even  with  shared
histopathologies or organ of origin, genomics has unveiled a remarkably complicated biologic
landscape, with metastatic malignancies manifesting molecular complexity that differs from
tumor to tumor.2-4 In order to impact heterogeneous cancers in a precise manner, one must
customize (or personalize) the therapeutic regimen. This new precision-personalized model
differs  from conventional  strategies  for  cancer  management  in  that  it  reflects  a  patient-
centric,  rather  than  drug-centric  approach.  This  shift  in  oncology  treatment  paradigms
requires that outcome analyses are adapted to accurately assess this emerging, innovative
strategy for patient care.
Recently, some investigators have suggested5 that the outcomes of precision oncology trials
should  be  re-analyzed  using  the  intention-to-treat  (ITT)  methodology,  which  was  first
developed three decades ago, before the advent of molecularly matched therapy6 and four
decades  after  randomized  controlled  trials  (RCTs),  whose  problems  it  was  designed  to
remedy.7 RCTs  compare  two treatment  arms  in  patients  with  shared  histologies,  but  not
necessarily  shared  underlying  tumor  biologies.  These  trials  frequently  suffer  from  non-
compliance  and missing  outcomes,  making it  difficult  to  compare  the  two arms.  The ITT
analysis  resolves  issues  that  plagued  traditional  RCTs  by including  every  patient  who  is
randomized to both arms, regardless of protocol deviations, non-compliance, withdrawal, and
any other reason(s) that supervenes after randomization.8 
It is not surprising that when ITT analyses are performed in the context of precision oncology
trials,  the  response  rates  are  dramatically  lowered. Combining  all  patients,  whether
unmatched, matched, untreated or treated, is akin to combining both arms of randomized
clinical  trials  in  order  to  assess  whether  either  investigational  regimen  is  effective,  and
institutes  anachronistic  arbitrary  statistical  assumptions.  The  first  time  we  administered
individualized combination therapies to  patients  with lethal  malignancies in the I-PREDICT
study,9 for  example,  patients  had  better  outcomes  if  they  had high  percentages  of  their
identified genomic alterations matched. This is not surprising since metastatic tumors have
remarkably complex molecular portfolios and each tumor tends to be unique.2-4 Patients with
high matching scores (>50%; usually reflecting more than half of their genomic alterations
being  matched)  had  significantly  longer  progression-free  (PFS)  and  overall  survival,  and
objective response rates (ORR) of 45% versus 16% for low matching scores (≤50%).9 A re-
analysis that includes all patients consented, however, reduces the ORR to 11%,5 and does
not  differentiate  between  patients  that  were  well  matched  versus  poorly  matched.  The
reduction in ORR is because only 49% of  patients received matched treatment;  the most
common  reason  patients  were  not  treated  was  because  their  disease  was  advanced  at
consent (a not uncommon problem in precision medicine trials) and they deteriorated or died
before therapy could be started.9 ITT re-analysis is misleading in the non-randomized trial
setting where treatment assignment is not by chance alone. 
To further demonstrate the issues inherent in an ITT analysis for precision cancer medicine
studies,  we  take  as  examples  three  randomized  trials  critical  for  U.S.  Food  and  Drug
Administration (FDA) approval (Table 1): crizotinib (ALK inhibitor, lung cancer);10 trastuzumab
(Her2  antibody,  gastro-oesophageal  cancers);11 and  vemurafenib  (BRAF  inhibitor,
melanoma).12 An average of 3,626 patients (range: 2,107 to 4,967) were screened in order to
find an  average  of  539 patients  (15% of  screened patients)  with  the  cognate  alteration.
Hence, the reported crizotinib ORR was 65% in the treated ALK-rearranged patients. Had half
of the screened patients (i.e., ITT for that arm of the randomized trial) been included, the ORR
would be only 4.6%. We already know that <5% of lung cancers harbor ALK rearrangements.
The actual ORR versus recalculated ITT ORR were similarly 47.3% versus 7.3% (trastuzumab)
and  48.4%  versus  10.1%  (vemurafenib).  These  drugs  are  now  approved  by  multiple
regulatory agencies, with widely demonstrated high levels of efficacy.  The original studies
clearly  demonstrated  the  clinical  utility  of  molecular  profiling  and  precision  targeting  of
tumors. An ITT re-analysis is misleading and invalid since the very purpose of the studies was
to  identify  the  genetic  confounder(s)  that  predict  response,  rather  than  to  eliminate
confounders in the unselected patient populations that are the subject of RCTs. Indeed, as
shown in Table 1, one must find the right patients for these drugs, even if it means screening
thousands of individuals and treating only a small subset. 
Other examples such as those of NTRK fusion matched therapy are also pertinent. Based upon
a recently reported analysis of 13,467 adult tumor samples from The Cancer Genome Atlas
(TCGA), we showed that  NTRK fusions were observed in 0.31% of cancers.13 Moreover, in a
non-randomized New England Journal of Medicine study of larotrectinib, a highly selective TRK
inhibitor,  75%  of  the  55  treated  patients  had  an  objective  response.14 Based  upon  the
incidence of these mutations, we calculated that 17,742 patients would need to be screened
in  order  to  accrue  the  55 patients  that  were  initially  consented.  Thus,  based on  the ITT
methodology, we would calculate a 0.23% objective response rate for larotectinib. This is, of
course, not a true reflection of the efficacy of this now FDA-approved drug.
Precision-personalized medicine unlocks a new paradigm for addressing the cancer problem.
Some of  the  results  to  date  have  been stunning,  including  the  near-normalization  of  life
expectancy  for  chronic  myelogenous  leukemia—a  previously  lethal  disease—when  the
molecular BCR-ABL aberration is targeted by cognate inhibitors,15 and the high rate of durable
responses  in  solid  tumors  with  ALK  rearrangements  or  NTRK fusions  after  ALK  or  NTRK
targeting,  respectively.10,14 Evaluating  current  outcomes  requires  analytic  methodologies
modernized for the patient-centered model. 
It took 40 years to develop a statistical analysis (ITT analysis) that addressed the problems of
RCTs. Though precision medicine may be in its nascence, it has become increasingly apparent
that  we  need  to  now  focus  on  therapeutic  approaches  that  lead  to  more  dramatic
improvements in ORRs and survival endpoints, and those approaches should be based on a
deep scientific understanding of individual  tumor biology.  As we hone our appreciation of
cancer biology and drug targeting, retrofitting decades old statistical methods, such as the ITT
analysis developed for unselected patient populations yields misleading conclusions. Properly
assessing  outcomes  requires  analytic  methodologies  modernized  for  the  patient-centered
model that specifically seeks out the biomarkers of responsiveness and, hence, represents the
tenets of precision-personalized medicine.
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TABLE
Table 1. Randomized clinical trials with molecularly matched targeted agents.
Author Study Disease Investigatio
nal agent
Control Screen
ed
Randomiz
ed
Investigatio
nal arm
Evaluable
for CR + PR
in
investigatio
nal arm
Reported
CR  +  PR  in
investigatio
nal arm
Reported
ORR
Intention-to-
treat ORR*
Shaw  et
al,10
2013
PROFILE
1007
Locally  advanced
or  metastatic  ALK-
positive  lung
cancer  who  had
received  one  prior
platinum-based
regimen
Crizotinib Chemothera
py  with
pemetrexed
or docetaxel
4967 347 173 173 113 65.3% 4.6%
Bang  et
al,11
2010
ToGA Gastric  or  gastro-
oesophageal
junction  cancer
were  eligible  for
inclusion  if  their
tumours  showed
overexpression  of
HER2  protein  by
immunohistochemi
stry  or  gene
amplification  by
fluorescence in-situ
hybridisation
Trastuzumab
plus
chemotherap
y
Chemothera
py alone
3803 594 298 294 139 47.3% 7.3%
Chapma
n et al,12
2011
BRIM 3 Previously
untreated,
metastatic
melanoma with the
BRAF  V600E
mutation
Vemurafenib Dacarbazine 2107 675 337 219 106 48.4% 10.1%
* Calculated based upon half of the screened patients.
Abbreviations: CR = complete response; PR = partial response; ORR = objective response rate
